Dr. Gao is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd Unit 1374
U Texas Md Anderson Cancer Center, Hem/Onc Dept
Houston, TX 77030Phone+1 713-792-2830
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2010 - 2013
University of Wisconsin Hospitals and ClinicsResidency, Internal Medicine, 2006 - 2010
University of Kansas School of MedicineClass of 2006
Certifications & Licensure
FL State Medical License 2021 - Present
AZ State Medical License 2023 - 2026
TN State Medical License 2023 - 2026
WA State Medical License 2023 - 2026
GA State Medical License 2023 - 2025
LA State Medical License 2023 - 2025
MS State Medical License 2023 - 2025- American Board of Internal Medicine Medical Oncology
- Join now to see all
Clinical Trials
- Pemetrexed Disodium in Treating Patients With Previously Treated Metastatic Urothelial Cancer Start of enrollment: 2017 May 09
Publications & Presentations
PubMed
- 1399 citationsB cells and tertiary lymphoid structures promote immunotherapy responseBeth A. Helmink, Sangeetha M. Reddy, Jianjun Gao, Shaojun Zhang, Rafet Basar
Nature. 2020-01-23 - 29 citationsA phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy.Pavlos Msaouel, Sangeeta Goswami, Peter F Thall, Xuemei Wang, Ying Yuan
Science Translational Medicine. 2022-04-20 - 15 citationsTAM kinase inhibition and immune checkpoint blockade- a winning combination in cancer treatment?Pavlos Msaouel, Giannicola Genovese, Jianjun Gao, Suvajit Sen, Nizar M. Tannir
Expert Opinion on Therapeutic Targets. 2021-02-01
Journal Articles
- Author Correction: Fecal Microbiota Transplantation for Refractory Immune Checkpoint Inhibitor-Associated ColitisMatthew T Campbell, Jennifer A Wargo, John R Stroehlein, Padmanee Sharma, Sumit K Subudhi, Gottumukkala S Raju, Jianjun Gao, Alexander J Lazar, Dipen M Maru, Michael T..., Nature
- Fecal Microbiota Transplantation for Refractory Immune Checkpoint Inhibitor-Associated ColitisJohn R Stroehlein, Sumit K Subudhi, Jennifer A Wargo, Dipen M Maru, Gottumukkala S Raju, Jianjun Gao, Matthew T Campbell, Michael T Tetzlaff, Padmanee Sharma, Nature
Lectures
- A pilot presurgical study evaluating anti-PD-L1 durvalumab (durva) plus anti-CTLA-4 tremelimumab (treme) in patients (pts) with high-risk muscle-invasive bladder carci...2019 ASCO Annual Meeting - 6/1/2019
- A pilot randomized study evaluating nivolumab (nivo) or nivo + bevacizumab (bev) or nivo + ipilimumab (ipi) in patients with metastatic renal cell carcinoma (MRCC) eli...2019 ASCO Annual Meeting - 6/1/2019
- A pilot randomized study evaluating nivolumab (nivo) or nivo + bevacizumab (bev) or nivo + ipilimumab (ipi) in patients with metastatic renal cell carcinoma (MRCC) eli...2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Press Mentions
Immunotherapy Clinical Trial Puts Stage IV Kidney Cancer into RemissionMarch 29th, 2023- MD Anderson Research Highlights for April 13, 2022April 13th, 2022
B-cell Enrichment Predictive of Immunotherapy Response in Melanoma, Sarcoma and Kidney CancerFebruary 25th, 2020- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
